Clinical Trials Logo

Filter by:
NCT ID: NCT05874648 Not yet recruiting - Cancer Clinical Trials

PRediction Of Five Usual Tumors Using Blood Test for Risk Assessment and Early Detection

PROFUTURE
Start date: July 7, 2023
Phase:
Study type: Observational

Liquid biopsy technology based on cell-free nucleic acids and protein characteristics has unique advantages and significant application prospects in cancer early detection. The purpose of this study is to collect peripheral blood samples from participants with new diagnosis of cancer and from participants who do not have a diagnosis of cancer in order to develop machine learning models for discovering cancer from non-cancer.

NCT ID: NCT05874622 Completed - Clinical trials for Rheumatoid Arthritis

A Phase I Clinical Study of VC005 Tablets in Subjects With Rheumatoid Arthritis.

Start date: June 12, 2023
Phase: Phase 1
Study type: Interventional

This is a randomized, double-blind, dose-escalating, placebo-controlled phase Ib clinical study.

NCT ID: NCT05874596 Recruiting - Stroke, Acute Clinical Trials

Whole-process Quality Improvement of Endovascular Treatment Basd on an AI-aided Clinical Feedback System

Start date: June 22, 2023
Phase: N/A
Study type: Interventional

A clustered randomized control trial to evaluate whether multi-aspect intervention based on an AI-aided clinical feedback system could improve the quality of EVT and functional outcome of patients.

NCT ID: NCT05874570 Recruiting - Clinical trials for Helicobacter Pylori Infection

Doxycycline for Helicobacter Pylori Rescue Treatment

Start date: June 20, 2023
Phase: Phase 4
Study type: Interventional

Current guidelines have recommended classical bismuth-containing quadruple therapy including proton-pump inhibitor, bismuth, tetracycline, metronidazole as the empirical rescue therapy. However, tetracycline is clinically unavailable in China and the high frequency of adverse events of bismuth quadruple therapy often result in poor compliance, which limited the applicability of this recommendation. This study aimed to compare the efficacy and tolerability of a 14-day bismuth-containing quadruple rescue therapy in which tetracycline was replaced by doxycycline.

NCT ID: NCT05874544 Recruiting - Clinical trials for Helicobacter Pylori Infection

Rescue Therapy for Helicobacter Pylori Infection

Start date: May 16, 2023
Phase: Phase 4
Study type: Interventional

Dual therapy containing vonoprazan and amoxicillin had showed excellent eradication results with Helicobacter pylori first-line treatment. However, no study has examined its efficacy for H. pylori rescue treatment. Rifabutin has low antibiotic resistance, superior antibacterial activity in vitro, and stability in the gastric acid environment. Several studies have confirmed the efficacy of rifabutin-containing triple therapy as a first-line or rescue treatment for H. pylori. The purpose of this study was to evaluate the efficacy and safety of dual therapy vesus rifabutin-containing triple therapy versus classical bismuth-containing quadruple therapy as rescue therapy for the eradication of refractory Helicobacter pylori.

NCT ID: NCT05874518 Completed - Electroacupuncture Clinical Trials

Clinical Observation of Warm Needling Combined With and Electroacupuncture Therapy on Ovulatory Dysfunction

Start date: December 1, 2021
Phase: N/A
Study type: Interventional

To observe the effect of warm needling combined with electroacupuncture on the ovulation promotion rate and pregnancy rate in luteinized unruptured follicle syndrome (LUFS).

NCT ID: NCT05874310 Recruiting - Clinical trials for X-Linked Retinitis Pigmentosa

Gene Therapy for Subjects With RPGR Mutation-associated X-linked Retinitis Pigmentosa

Start date: February 1, 2023
Phase: Early Phase 1
Study type: Interventional

A clinical trial of gene therapy for patients with X-linked retinitis pigmentosa (XLRP).

NCT ID: NCT05873972 Not yet recruiting - Clinical trials for Colorectal Cancer Liver Metastases

Multimodal Model for Efficacy Prediction Cetuximab in Colorectal Cancer Liver Metastasis Patient

Start date: June 1, 2023
Phase: N/A
Study type: Interventional

Establishment and validation of the deep learning model of Cetuximab efficacy in simultaneous RAS wild unresectable CRLM patients

NCT ID: NCT05873803 Recruiting - Clinical trials for Chronic Rhinosinusitis With Nasal Polyps

The Study of GR1802 in Patients With Chronic Rhinosinusitis With Nasal Polyps

Start date: February 8, 2023
Phase: Phase 2
Study type: Interventional

This is a multi-center, randomized, double blind, placebo-controlled study to evaluate the efficacy, safety, PK, PD and immumogenicity of GR1802 injection in comparison to placebo in addition to a background treatment of mometasone furcate nasal spray (MFNS) in patients with chronic rhinosinusitis with nasal polyposis (CRSwNP). Patients will receive GR1802 injection or Placebo every 2 Weeks.

NCT ID: NCT05873777 Recruiting - Clinical trials for Positron-Emission Tomography

68Ga-FAPI-LM3 PET/CT Imaging in Patients With FAP/SSTR2 Positive Disease and Compared With 18F-FDG

Start date: April 9, 2023
Phase: N/A
Study type: Interventional

As a new dual receptor (SSTR2 and FAP) targeting PET radiotracer, 68Ga-FAPI-LM3 is promising as an excellent imaging agent applicable to SSTR2 positive diseases. In this research, we investigate the safety, biodistribution and radiation dosimetry of 68Ga-FAPI-LM3 in healthy volunteers. Moreover, we evaluate the potential usefulness of 68Ga-FAPI-LM3 positron emission tomography/computed tomography (PET/CT) for the diagnosis of lesions in SSTR2 positive diseases, and compared with 18F-FDG PET/CT.